Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EPS (Weighted Average and Diluted) (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 50.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.04 through Dec 2025, up 20.0% year-over-year, with the annual reading at -$0.04 for FY2025, 20.0% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Guided Therapeutics, roughly flat from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.0 in Q3 2021 to a low of -$0.09 in Q2 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.02 across 5 years, with a median of -$0.02 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 84.21% in 2021 and later crashed 689.24% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then fell by 0.0% to -$0.04 in 2022, then soared by 77.07% to -$0.01 in 2023, then crashed by 118.04% to -$0.02 in 2024, then skyrocketed by 50.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for GTHP at -$0.01 in Q4 2025, -$0.01 in Q3 2025, and -$0.01 in Q2 2025.